Court Opinion

ID: 4692123
Source: CourtListenerOpinion
Date Created: 2021-06-02 14:05:08.671487+00
Date Added: 2024-06-11T08:05:13.667243
License: Public Domain

IN THE SUPERIOR COURT OF THE STATE OF DELAWARE

Izabella Shealy,                             )
                                             )
                Plaintiff,                   )
                                             )     C.A. No.: N21C-01-068 PEL
       v.                                    )
                                             )
Boston Scientific Corporation,               )
                                             )
                Defendants.                  )

                              Submitted: April 8, 2021
                                Decided: June 1, 2021

                          OPINION AND ORDER
                   ON DEFENDANT’S MOTION TO DISMISS

                    DENIED IN PART/GRANTED IN PART

Robert J. Leoni, Esquire, Shelby & Leoni, 221 Main Street Wilmington, DE 19804,
Attorneys for Plaintiff. Shanin Specter, Esquire, Lee B. Balefsky, Esquire Tracie L.
Palmer, Esquire, Kline & Specter, P.C., 1525 Locust Street Philadelphia, PA 19102,
of Counsel - Attorney for Plaintiff.

Colleen Shields, Esquire and Alexandra D. Rogin, Esquire Eckert, Seamans, Cherin
& Mellott LLC, 221 Main Street, Stanton, DE 19804, Attorneys for Defendant

Jones, J.
                                 INTRODUCTION

      Plaintiff, Izabelle Shealy, has brought suit against the Defendant, Boston

Scientific Corporation (“Boston Scientific”), alleging numerous claims sounding in

strict liability, negligence, and breach of various warranties. Plaintiff’s claims arise

out of personal injuries she claims to have suffered from a mesh device that was

surgically implanted in her. Plaintiff alleges that this mesh device was defectively

designed and manufactured by Boston Scientific. The Defendant has moved to

dismiss the Complaint on the following grounds: (1) the Complaint fails to satisfy

the pleading requirements of the Superior Court; (2) the failure to warn claims are

barred by the learned intermediary doctrine; (3) any design or manufacturing defect

claim should be dismissed for failure to specify a defect; (4) the breach of warranty

claim fails because Plaintiff has failed to allege how or when the alleged

representations of the warranty were made; (5) there is no allegation that the

Defendant’s device was the proximate cause of Plaintiff’s injuries; and             (6)

Plaintiff’s request for punitive damages should be stricken because she has not

alleged sufficient facts to support a punitive damages claim under either Delaware

or New York law. The parties appear to agree the substantive law of New York

controls this action. For purposes of this motion the Court will accept that New York

                                              2
law applies.1 For the reasons set forth below, Boston Scientific’s Motion to Dismiss

is GRANTED IN PART and DENIED IN PART.

                                              BACKGROUND

         The background of this case is taken from the factual allegations set forth in

Plaintiff’s Complaint, which this court must accept as true in deciding the motion to

dismiss.

         Plaintiff is a resident of New York. On January 7, 2019, Plaintiff underwent

implantation of a pelvic mesh device manufactured by Defendant called the Obtryx.

The surgery was performed in Santa Monica, California. As a result of the implant

Plaintiff has suffered pain, erosion, urinary problems, dyspareunia, organ

perforation, and vaginal scarring related to complications from Defendant’s product.

This included an additional surgery to remove eroded mesh performed at UCLA

Medical Center on July 12, 2019. Plaintiff’s Complaint was filed on January 11,

2021. The Complaint asserted claims against Defendant based on Negligence (Count

I), Breach of Warranty (Count II), and Failure to Warn (Count III).

         Defendant filed a Motion to Dismiss the action on February 23, 2021. The

parties have fully briefed the Motion to Dismiss and this Opinion represents the

Court’s decision on that Motion.

1
 Plaintiff is a resident of New York. The two medical procedures related to the mesh implant occurred in California.
This Court’s review of California law suggests that the result reached in this opinion is the same if the Court applied
California law to this analysis.
                                                              3
                                       STANDARD OF REVIEW

         Under Superior Court Rule 12(b)(6), the Court may dismiss a claim for failure

to state a claim upon which relief can be granted only where the plaintiff cannot

recover under any reasonably conceivable set of circumstances or facts susceptible

of proof that may be inferred from the allegations. The Court accepts the well-pled

allegations of the complaint as true and draws “all reasonable information that

logically flow from those allegations in favor of the non-moving party.”2 Under

Delaware law, in order to survive a motion to dismiss for failure to state a claim, a

complaint need only give general notice of the claim asserted and will not be

dismissed unless it is clearly without merit, either as a matter of law or fact. 3 A

Court can dismiss for failure to state a claim on which relief can be granted only if

“it appears with reasonable certainty that the plaintiff could not prove any set of facts

that would entitle her to relief.”4

         Under Del. Super. Ct. Civ. Rule 9(b) a plaintiff must plead negligence with

particularity. The purpose of Rule 9(b) is to apprise the adversary of the acts or

omissions by which it is alleged that a duty has been violated so that an opponent is

able to prepare a defense.5 Under Rule 9(b) it is usually necessary to allege only

2
  Tanesha Maretta Williams v. Newark Country Club, 2016 WL 6781221 at 1 (Del.Super., November 2, 2016);
William L. Spence Jr., v. Allison J. Funk, et al., 396 A.2d 967, 968 (Del. 1978); Richard Clinton, et al. v. Enterprise
Rent-a-Car Co., et al., 977 A.2d 892, 895 (Del. 2009).
3
  Wilen v. Pollution Control Industries, Inc., Del. Ch. C.A. No 7254-NC (Consolidate). Harnett, V.C. (Oct 15,
2984).
4
  Rammuno v. Cawley, 705 A 2d 1029, 1034 (Del 1998).
5
  Chesapeake & Potomac Tel. Co. of Maryland v. Chesapeake Utilities Corp., 436 A2d 314, 338 (Del 1981).
                                                              4
sufficient facts out of which a duty is implied and a general averment of failure to

discharge that duty.6

                                FAILURE TO WARN CLAIMS

        Defendant alleges that the learned intermediary doctrine bars all failure to

warn claims contained in Count III of Plaintiff’s Complaint.7 Under the learned

intermediary doctrine a “medical professional acts as an ‘learned intermediary’

between the manufacturer [of a medical device] and the patient” and the

manufacturer is relieved of any responsibility to directly warn the patient. 8 Thus, a

manufacturer’s duty to warn in this context only extends to the physician. However,

the learned intermediary doctrine does not compel dismissal of claims that warning

labels were insufficient, since these claims are premised on Defendant’s failure to

provide proper warnings to Plaintiff’s prescribing medical professionals, and not on

Defendant’s failure to warn Plaintiff directly. 9

        In the instant case Plaintiff has alleged the following in her Complaint:

            • Defendant has known and continue to know that some of
              the predicate products for the Pelvic Mesh Products had
              high failure and complication rates, resulting in the recall of
              some of these predicate Device; that there were and are
              differences between the Defendant’s Pelvic Mesh Products
              and some or all of the predicate products, rendering them
              unsuitable for designation as predicate products; that
              significant differences exist and exited between the Pelvic
              Mesh Products and their predecessors and predicate
              products, such that the disclosures to the FDA were and are
6
  State Farm Fire & Cas., Co v. Gen. Elec. Co., 2009 WL 5177156 (Del. Super., 2009).
7
  Bukowski v. CooperVision Inc., 592 NY.2d 807, 809 (N.Y. App. Div. 1993).
8
  Banker v. Hoehn., 718 N.Y. S.2d 438, 440 (N.Y. App. Div. 2000).,
99
   See Martin v. Hacker., 83 N. Y 2d 1, 9 (N.Y. 1993).
                                                          5
           incomplete and misleading; and that the Pelvic Mesh
           Products were and are causing numerous patients severe
           injuries and complications. The Defendants suppressed
           information and failed to accurately and completely
           disseminate or share this and or critical information with the
           FDA, health care providers, or the patients. As a result, the
           Defendants actively and intentionally misled and continue
           to mislead the public, including the medical community,
           health care providers and patients, into believing that the
           Pelvic Mesh products and the procedure for implantation
           was and are safe and effective, leading to the prescription
           for and implantation of the Pelvic Mesh products into the
           Plaintiff. (Id. at ¶ 12).
         • Causation: After, and as a result of the implantation of the
           Medical Devices, Plaintiff Izabella Shealy suffered serious
           bodily injuries, including, but not limited to erosion and
           other injuries similar to the ones described in the FDA’s
           Public Health Advisory of October 20, 2008. (¶ 48).
         • Causation: These injuries would not have occurred but for
           the defective nature of the products implanted and/or
           Defendant’s wrongful conduct. (Id. at ¶ 49.)
         • As a result of having the Medical Devise implanted into her,
           Izabella Shealy has experienced significant mental and
           physical pain and suffering, and she has sustained
           permanent injury. (Id.. at ¶ 50.)

      At this stage of the proceedings, the above allegations lead this Court to

conclude that the Plaintiff has sufficiently pled a failure to warn claim. The

Complaint clearly indicates that the Defendant mislead the medical community and

the Plaintiff’s injuries would not have occurred but for the Defendant’s wrongful

conduct. By reasonable inference from the facts alleged, this would include the

treating physician electing another product had they not been misled. While the

Complaint could have been more clearly drafted by containing a specific allegation

that the doctor who implanted the Obtryx would not have done so had they received
                                           6
a proper warning, the Complaint is sufficient (although barely) at this stage of the

proceedings to withstand a motion to dismiss on the learned intermediary doctrine

and the proximate cause requirements that follow from that doctrine. At the motion

to dismiss stage there is a reasonable set of facts that exist that could place liability

against the defendant for failure to warn.

        Accordingly, Defendant’s Motion to Dismiss is DENIED with respect to the

failure to warn claim described in Count III of the Complaint.

                             BREACH OF WARRANTY CLAIM

        Defendant next seeks to dismiss Plaintiff’s Count II for breach of warranty.

Defendant argues that the Complaint “does not describe any representation that

Boston Scientific made to [Plaintiff] or her prescribing physician” or where or how

such a representation was made.10 An express warranty is an “affirmation of fact or

promise made by the seller to the buyer which relates to goods and becomes part of

the basis of the bargain.”11 To state a claim for breach of an express warranty under

New York law, a plaintiff must prove “that an express warranty existed, was

breached, and that plaintiff had relied on that warranty.”12 The Plaintiff must allege

where, when or how the alleged promise or statement was provided to her or her

physicians.13

10
   Def.’s Mot. To Dismiss at 7.
11
   N.Y. U.C.C. S 2-313(1)(a); See Friedman v. Medtronic, Inc. 345 N.Y.S.2d 637, 643 (N.Y. App. Div. 1973).
12
   Reed v. Pfizer, Inc., 839 F.Supp.2d 571, 578 (E.D.N.Y. 2012).
13
   Fisher v. APP PHARMACEUTICALS, LLC, et al., 783 F.Supp.2d 424, 431 (S.D.N.Y. 2011).
                                                          7
      Plaintiff argues that she has pled the breach of warranty claim adequately,

pointing to Paragraph 17 of the Complaint. In that section of the Complaint, she

alleges: “Defendant provided incomplete, insufficient, and misleading training and

information to physicians, in order to increase the number of physicians utilizing the

Pelvic Mesh Products, and thus increased the sales and also leading to the

dissemination of inadequate and misleading information to patients, including

plaintiff.” The Plaintiff also points to paragraphs 5-8, 24, 25 and 46-50 of the

Complaint. These paragraphs contain, among other allegations, the following:

         • “…these products contain a monofilament polypropylene
           mesh intended for the treatment of stress urinary
           incontinence. Despite claims that this material is inert, the
           emerging scientific evidence suggests that this material is
           biologically incompatible with human tissue and promotes
           an immune response in a large subset of the population
           receiving Defendant’s Pelvic Mesh Products containing this
           material.” (¶ 5).
         • Defendant’s Pelvic Mesh Products have been and continue
           to be marketed to the medical community and to patients as
           safe, effective, reliable, medical device; implanted by safe
           and effective, minimally invasive surgical techniques for
           the treatment of medical conditions, primarily pelvic organ
           3 prolapse and stress urinary incontinence, and as safer and
           more effective as compared to the traditional products and
           procedures for treatment, and other competing Pelvic Mesh
           Products. (¶ 6).
         • The Defendant has marketed and sold the Pelvic Mesh
           Products to the medical community at large and patients
           through carefully planned, multifaceted marketing
           campaigns and strategies. These campaigns and strategies
           include, but are not limited to, aggressive marketing to
           health care providers at medical conferences, hospitals,
           private offices, and include the provision of valuable cash
           and non-cash benefits to health care providers. Also utilized
                                             8
                 are documents, brochures, and websites, offering
                 exaggerated and misleading expectations as to the safety
                 and utility of the products. (¶ 7).
             • Defendant failed to undertake their duties to properly know
                 the qualities of their product and in representations to
                 Plaintiff and/or to Plaintiff’s healthcare providers, to and
                 concealed and intentionally omitted [] material information
                 (¶ 24).14
             • These injuries would not have occurred but for the defective
                 nature of the products implanted and/or Defendant’s
                 wrongful conduct. (¶ 49).
           These allegations, taken together, are sufficient to allege an express breach of

warranty claim. Defendant’s Motion to Dismiss is DENIED with respect to the

breach of warranty claims detailed in Count II of the Complaint.

                                REMAINING NELIGENCE CLAIMS

           Defendant alleges that the remaining negligence claims found in Count I of

the Complaint which are not based on a failure to warn theory are not adequately

pled. With respect to the design and manufacturing defect claims found in Count I,

Defendant maintains that Plaintiff’s allegations fail to establish the existence of a

defect or to tie any particular defect to her injuries. According to Defendant, the

Plaintiff does little more than assert the bare elements of a negligence claim.

           Plaintiff has alleged the following in her complaint:

               •    Moreover, these products contain a monofilament polypropylene mesh
                   intended for the treatment of stress urinary incontinence. Despite claims
                   that this material is inert, the emerging scientific evidence suggests that
                   this material is biologically incompatible with human tissue and
                   promotes an immune response in a large subset of the population
                   receiving Defendant’s Pelvic Mesh Products containing this material.
                   This immune response promotes degradation of the pelvic tissue and can
14
     The Complaint contains eleven specific pieces of allegedly omitted material information in this paragraph.
                                                               9
  contribute to the formation of severe adverse reactions to the mesh. (¶
  5).
• Defendant’s Pelvic Mesh Products have been and continue to be
  marketed to the medical community and to patients as safe, effective,
  reliable, medical device; implanted by safe and effective, minimally
  invasive surgical techniques for the treatment of medical conditions,
  primarily pelvic organ prolapse and stress urinary incontinence, and as
  safer and more effective as compared to the traditional products and
  procedures for treatment, and other competing Pelvic Mesh Products. (¶
  6)
• The Defendant has marketed and sold the Pelvic Mesh Products to the
  medical community at large and patients through carefully planned,
  multifaceted marketing campaigns and strategies. These campaigns and
  strategies include, but are not limited to, aggressive marketing to health
  care providers at medical conferences, hospitals, private offices, and
  include the provision of valuable cash and non-cash benefits to health
  care providers. Also utilized are documents, brochures, and websites,
  offering exaggerated and misleading expectations as to the safety and
  utility of the products. (¶ 7)
• Contrary to the Defendant’s representations and marketing to the
  medical community and to the patients themselves, the Defendant’s
  Pelvic Mesh Products have high failure, injury, and complication rates,
  fail to perform as intended, require frequent and often debilitating re-
  operations, and have caused severe and irreversible injuries, conditions,
  and damage to a significant number of women, including the Plaintiff,
  making them defective under the law. The defects stem from any or all
  of the following:
             a. the use of polypropylene material in the Mesh itself and the
          immune reaction that results, causing adverse reactions and
          injuries;
             b. the design of the Pelvic Mesh Device to be inserted
          transvaginally into an area of the body with high levels of
          bacteria, yeast, and fungus that adhere to the mesh causing
          immune reactions and subsequent tissue breakdown and adverse
          reactions and injuries;
             c. biomechanical issues with the design of the mesh that create
          strong amounts of friction between the mesh and the underlying
          tissue that subsequently cause that tissue to degrade resulting in
          injury

                                  10
                               d. the use and design of anchors in the Pelvic Mesh Products
                            which when placed correctly are likely to pass through and injure
                            major nerve routes in the pelvic region.
                               d. degradation of the mesh itself over time which causes the
                            internal tissue to degrade resulting in injury.
                               e. the welding of the mesh itself during production which
                            creates a toxic substance that contributes to the degradation of
                            the mesh and host tissue alike.
                               f. the design of trocars, as Device to insert the Pelvic Mesh
                            Products into the vagina, are defective because the device
                            requires tissue penetration in nerve rich environments which
                            results frequently in the destruction of nerve endings causing
                            pain and other injuries. (¶ 8)

           These allegations, taken together, are sufficient to state claims for failure to

warn and sufficiently plead that defects in the Obryx device were the proximate

cause of the Plaintiff’s injuries.

                                    MANUFACTURING DEFECT

           To state a claim for a manufacturing defect under New York law, a plaintiff

must allege that (1) the product was defective due to error in the manufacturing

process and (2) the defect was the proximate cause of Plaintiff’s injury.15 Defendant

alleges that any claims premised on a manufacturing defect fail because Plaintiff:

(1) concedes that the devices at issue were in the condition intended by Boston

Scientific when they Boston Scientific’s possession (Compl. ¶18); (2) fails to

identify a particular design defect in the devices; and (3) fails to plead that any

alleged defect plausibly caused her injuries. Defendant is correct that the Plaintiff

has alleged that the devices at issue were in the condition intended by Boston

15
     Williamson v. Stryker Corp., 2013 WL 3833081, at 4 (S.D.N.Y. July 23, 2013).
                                                            11
Scientific when they left Boston Scientific’s possession. There is no alternative

pleading in the complaint that relates to a manufacturing defect that is premised on

an allegation that the Obtryx device was in the condition other then what Boston

Scientific intended when it left the company’s possession.                On this basis,

Defendant’s motion to dismiss claims based on a manufacturing defect is

GRANTED.16

                                               DESIGN DEFECT

           To state a cause of action for a design defect, Plaintiff must allege that the

product was unreasonably dangerous for its intended use and must allege with

sufficient specificity how the design of the product was defective.17 According to

Boston Scientific, Plaintiff has not done this. In paragraph 5 and 6 of the Complaint

(set forth above) plaintiff alleges that Defendant designed the Obtryx to contain

polypropylene, a material they knew was incompatible with tissues found in the

human body. The Complaint further alleges that Plaintiff’s tissue rejected the

Obtryx, causing her injury. These allegations are sufficient to allege a design defect

in the Obtryx. Defendant’s Motion to Dismiss with respect to Plaintiff’s claim for

design defect is DENIED.

16
     See Zetz v. Boston Scientific, 398 F Supp 3rd 700 (E.D. Cal 2019).
17
     Tears v. Bos. Sic Corp., 344 F Supp 3rd 500, 510 (S.D.N.Y 2018).
                                                               12
                         PUNITIVE DAMAGES CLAIM

      Plaintiff’s Complaint contains a demand for punitive damages. Defendant

seeks to dismiss Plaintiff’s claim for punitive damages. Defendant argues that

Plaintiff’s allegations that Boston Scientific acted in a “willful disregard for

Plaintiff’s safety cannot sustain a request for punitive damages”. Defendant also

seeks to strike Plaintiff’s request for punitive damages on the grounds that the other

claims in the Complaint should be dismissed. Plaintiff’s Complaint specifically

alleges the following:

          • Despite emerging scientific evidence that polypropylene is
            incompatible with human tissue, Defendant continues to market the
            Obtryx to the medical community. (Compl. At ¶ 5-6.)
          • Contrary to the Defendant’s representations and marketing…the
            Defendant’s products suffer from high failure, injury, and
            complication rates, fail to perform as intended, require frequent and
            often debilitating reoperations, and have caused severe reversible
            injuries. (Id. at ¶ 8.)
          • The Defendant has chronically underreported and withheld
            information about the propensity of Defendant’s pelvic Mesh Products
            to fail and cause injury and complications, and have misrepresented
            the efficacy and safety of the product, through various means and
            media, actively and intentionally misleading the FDA, the medical
            community, patients, and the public at large. (Id. at ¶. 9-10.)
          • Defendants “failed to accurately and completely inform the FDA,
            health providers and the patients. (Id. at ¶ 11.)
          • Defendant continues to mislead the public into believing their products
            are safe and effective. Id.

      At the motion to dismiss stage these allegations are sufficient for a punitive

damage claim to survive, as other causes of action have survived the instant motion

                                            13
to dismiss. Defendant’s Motion to Dismiss is DENIED with respect to Plaintiff’s

claim for punitive damages.

                                CONCLUSION

      In summary, the Defendant’s Motion to Dismiss is GRANTED with respect

for the claims for a manufacturing defect as described above. Defendant’s Motion

to Dismiss is DENIED with respect to all other claims found in the Complaint.

                                        /s/Francis J. Jones
                                        Francis J. Jones, Judge
cc:   File&ServeXpress

                                          14